Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results. Verstovsek, S., Mesa, R. A., Foltz, L. M., Gupta, V., Mascarenhas, J., Ritchie, E. K., Hoffman, R., Silver, R. T., Hong, W., Kremyanskaya, M., Trehu, E. G., Kantarjian, H. M., Gotlib, J. R. AMER SOC CLINICAL ONCOLOGY. 2014

View details for Web of Science ID 000358613203931